1α,25-Dihydroxyvitamin D3 Modulates CYP2R1 Gene Expression in Human Oral Squamous Cell Carcinoma Tumor Cells

Hormones and Cancer

Volumn 5, Issue 2, 2014, Pages 90-97

  Sundaram, Kumaran ^a   Sambandam, Yuvaraj ^a   Tsuruga, Eichi ^a   Wagner, Carol L ^a   Reddy, Sakamuri V ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALPHA 25 DIHYDROXYVITAMIN D3; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; CYTOCHROME P450; PROTEIN C FOS; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; CALCITRIOL; CALCITRIOL RECEPTOR; CHOLESTANETRIOL 26 MONOOXYGENASE; CYP2R1 PROTEIN, HUMAN; VITAMIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYP2R1 GENE; DRUG METABOLISM; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; WESTERN BLOTTING;

ANTHRACENES; BLOTTING, WESTERN; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHOLESTANETRIOL 26-MONOOXYGENASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MOUTH NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; VITAMINS;

EID: 84897988200     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-014-0170-5     Document Type: Article

References (45)

1. Bennett RG, Wakeley SE, Hamel FG, High RR, Korch C, Goldner WS (2012) Gene expression of vitamin D metabolic enzymes at baseline and in response to vitamin D treatment in thyroid cancer cell lines. Oncology 83(5): 264-272.
2. Blomberg Jensen M, Andersen CB, Nielsen JE, Bagi P, Jorgensen A, Juul A, Leffers H (2010) Expression of the vitamin D receptor, 25-hydroxylases, 1 alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J Steroid Biochem Mol Biol 121(1-2): 376-382.
3. Chen TC, Sakaki T, Yamamoto K, Kittaka A (2012) The roles of cytochrome P450 enzymes in prostate cancer development and treatment. Anticancer Res 32(1): 291-298.
4. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW (2004) Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 101(20): 7711-7715.
5. Chiang KC, Yeh CN, Hsu JT, Chen LW, Kuo SF, Sun CC, Huang CC et al (2013) MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase. J Steroid Biochem Mol Biol 138: 427-434.
6. Dalirsani Z, Farajnia S, Javadzadeh Y, Mehdipour M, Koozegari S (2012) The effects of 5-fluorouracil alone and in combination with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines. J Contemp Dent Pract 13(3): 345-350.
7. Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7(9): 684-700.
8. Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID, Telfer C, Melvin WT, Murray GI (2005) Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 11(20): 7369-7375.
9. Enepekides DJ, Black MJ, White JH (1999) The independent and combined effects of RAR-, RXR-, and VDR-selective ligands on the growth of squamous cell carcinoma in vitro. J Otolaryngol 28(2): 83-89.
10. Erdem NF, Carlson ER, Gerard DA, Ichiki AT (2007) Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg 65(9): 1725-1733.
11. Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF, Chen TC (2006) Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res 26(4A): 2567-2572.
12. Flynn G, Chung I, Yu WD, Romano M, Modzelewski RA, Johnson CS, Trump DL (2006) Calcitriol (1, 25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology 70(6): 447-457.
13. Freedman DM, Dosemeci M, McGlynn K (2002) Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med 59(4): 257-262.
14. Gedlicka C, Hager G, Weissenbock M, Gedlicka W, Knerer B, Kornfehl J, Formanek M (2006) 1, 25(OH)2Vitamin D3 induces elevated expression of the cell cycle inhibitor p18 in a squamous cell carcinoma cell line of the head and neck. J Oral Pathol Med 35(8): 472-478.
15. Goda T, Shimo T, Yoshihama Y, Hassan NM, Ibaragi S, Kurio N, Okui T, Honami T, Kishimoto K, Sasaki A (2010) Bone destruction by invading oral squamous carcinoma cells mediated by the transforming growth factor-beta signalling pathway. Anticancer Res 30(7): 2615-2623.
16. Guo J, Ma Z, Ma Q, Wu Z, Fan P, Zhou X, Chen L et al (2013) 1, 25(OH)2D3 inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Curr Med Chem 20(33): 4131-4141.
17. Hama T, Norizoe C, Suga H, Mimura T, Kato T, Moriyama H, Urashima M (2011) Prognostic significance of vitamin D receptor polymorphisms in head and neck squamous cell carcinoma. PLoS One 6(12): e29634.
18. Johnson NW, Jayasekara P, Amarasinghe AA (2011) Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontol 2000 57(1): 19-37.
19. Kraus JA, Dabbs DJ, Beriwal S, Bhargava R (2012) Semi-quantitative immunohistochemical assay versus oncotype DX((R)) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol 25(6): 869-876.
20. Krishnan AV, Trump DL, Johnson CS, Feldman D (2012) The role of vitamin D in cancer prevention and treatment. Rheum Dis Clin North Am 38(1): 161-178.
21. Krueger C, Hoffmann FM (2010) Identification of retinoic acid in a high content screen for agents that overcome the anti-myogenic effect of TGF-beta-1. PLoS One 5(11): e15511.
22. Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB et al (2004) Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64(18): 6511-6523.
23. Ma Y, Yu WD, Hidalgo AA, Luo W, Delansorne R, Johnson CS, Trump DL (2013) Inecalcitol, an analog of 1, 25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle 12(5): 743-752.
24. Malodobra-Mazur M, Paduch A, Lebioda A, Konopacka M, Rogolinski J, Szymczyk C, Wierzgon J et al (2012) VDR gene single nucleotide polymorphisms and their association with risk of oral cavity carcinoma. Acta Biochim Pol 59(4): 627-630.
25. Mao L, Hong WK, Papadimitrakopoulou VA (2004) Focus on head and neck cancer. Cancer Cell 5(4): 311-316.
26. Mishra A, Bharti AC, Varghese P, Saluja D, Das BC (2006) Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int J Cancer 119(12): 2840-2850.
27. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garcia A, Raimondi AR et al (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13(17): 4964-4973.
28. Nomura T, Shibahara T, Katakura A, Matsubara S, Takano N (2007) Establishment of a murine model of bone invasion by oral squamous cell carcinoma. Oral Oncol 43(3): 257-262.
29. Pandruvada SN, Yuvaraj S, Liu X, Sundaram K, Shanmugarajan S, Ries WL, Norris JS, London SD, Reddy SV (2010) Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Int J Cancer 126(10): 2319-2329.
30. Pelucchi C, Talamini R, Negri E, Levi F, Conti E, Franceschi S, La Vecchia C (2003) Folate intake and risk of oral and pharyngeal cancer. Ann Oncol 14(11): 1677-1681.
31. Piva MR, de Souza LB, Martins-Filho PRS, Nonaka CF, de Santana Santos T, Souza Andrade ES, Piva D (2013) Role of inflammation in oral carcinogenesis (part II): CD8, FOXP3, TNF-alpha, TGF-beta and NF-kappaB expression. Oncol Lett 5(6): 1909-1914.
32. Quan J, Johnson NW, Zhou G, Parsons PG, Boyle GM, Gao J (2012) Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms. Cancer Metastasis Rev 31(1-2): 209-219.
33. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF (1998) Human prostate cells synthesize 1, 25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7(5): 391-395.
34. Sundaram K, Mani SK, Kitatani K, Wu K, Pestell RG, Reddy SV (2008) DACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells. J Cell Biochem 103(6): 1747-1759.
35. Swami S, Krishnan AV, Wang JY, Jensen K, Horst R, Albertelli MA, Feldman D (2012) Dietary vitamin D(3) and 1, 25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 153(6): 2576-2587.
36. Turatti E, da Costa Neves A, de Magalhaes MH, de Sousa SO (2005) Assessment of c-Jun, c-Fos and cyclin D1 in premalignant and malignant oral lesions. J Oral Sci 47(2): 71-76.
37. Wagner CL, Taylor SN, Dawodu A, Johnson DD, Hollis BW (2012) Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus. Nutrients 4(3): 208-230.
38. Walker DD, Reeves TD, de Costa AM, Schuyler C, Young MR (2012) Immunological modulation by 1alpha, 25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck. Cytokine 58(3): 448-454.
39. Williams HK (2000) Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 53(4): 165-172.
40. Woloszynska-Read A, Johnson CS, Trump DL (2011) Vitamin D and cancer: clinical aspects. Best Pract Res Clin Endocrinol Metab 25(4): 605-615.
41. Wu W, Zhang X, Zanello LP (2007) 1alpha, 25-Dihydroxyvitamin D(3) antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma. Cancer Lett 254(1): 75-86.
42. Yunoki T, Kariya A, Kondo T, Hayashi A, Tabuchi Y (2013) The combination of silencing BAG3 and inhibition of the JNK pathway enhances hyperthermia sensitivity in human oral squamous cell carcinoma cells. Cancer Lett 335(1): 52-57.
43. Zeljic K, Supic G, Stamenkovic Radak M, Jovic N, Kozomara R, Magic Z (2012) Vitamin D receptor, CYP27B1 and CYP24A1 genes polymorphisms association with oral cancer risk and survival. J Oral Pathol Med 41(10): 779-787.
44. Zhang Q, Kanterewicz B, Shoemaker S, Hu Q, Liu S, Atwood K, Hershberger P (2013) Differential response to 1alpha, 25-dihydroxyvitamin D3 (1alpha, 25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations. J Steroid Biochem Mol Biol 136: 264-270.
45. Kingsley K, Bergman C, Keiserman M, Mobley C (2013) Oral cancer risk and vitamin D status, intake and supplementation. OA Cancer 1: 6.